Kiniksa Pharmaceuticals Provides Corporate Update
Kiniksa Pharmaceuticals, Ltd. - Class A (KNSA)
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
– ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by year end –– Cash balance increased by $170.4 million in 2025 to $414.1 million (unaudited) – LONDON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today provided a corporate update. “IL-1a & IL-1ß inhibition with ARCALYST is increasingly becoming the preferred second line treatment for patients with recurrent pericarditis. As of the end of 2025, approximately 18% of the multiple recurrence population was actively on ARCALYST therapy. In addition to driving further uptake in
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals, Ltd. - Class A news events
Weekly update
A roundup of the hottest topics
KNSA
News
- Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by analysts at Wedbush from $48.00 to $50.00. They now have an "outperform" rating on the stock.MarketBeat
- Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.MarketBeat
- Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in LondonGlobeNewswire
KNSA
Earnings
- 10/28/25 - Miss
KNSA
Sec Filings
- 1/14/26 - Form 8-K
- 1/12/26 - Form 8-K
- 1/9/26 - Form 4
- KNSA's page on the SEC website